Targeting tumor stem cells
Clinical trial at the University of Cincinnati involves targeting stem cells for personalized treatment of brain cancer
Researchers at the University of Cincinnati are leading the local arm of a study looking at ways to test for chemosensitivity in brain tumor stem cells to determine treatment response and outcomes for patients.
The primary site for the clinical trial is Marshall University in West Virginia, but Nicholas Marko, MD, director of the UC Brain Tumor Center, is leading the study locally.
“We are collecting tumor tissue from our patients and sending it to our collaborators at Marshall,” says Marko, who is also an associate professor of neurosurgery at the UC College of Medicine and a member of both the Gardner Neuroscience and Cancer Institutes. “These researchers grow stem cells from the tumor and then try to kill those cells with a number of chemotherapy drugs. The therapy that works best, based on these outcomes, is the patient’s designated study drug.”
Marko says when glioblastoma, an extremely malignant form of brain tumor, recurs in patients, the treatment options are often minimal, as surgery and radiation are not usually a possibility.
“In this study, patients with recurrent glioblastoma will receive standard therapy, including surgery if the tumor can be removed, and for the chemotherapy portion of their treatment, participants will be randomized between treatments chosen by the physician—standard cancer treatments—or the personally-selected, chemosensitivity drug. The goal is to see if this personalized therapy is more effective than standard of care.
“The idea is similar to when we test for bacterial sensitivity against antibiotics, in case of a bacterial infection. The test, in this case, uses sample specimens obtained following surgery for the treatment of brain cancer.”
Marko says that participants will be assessed by either brain MRI with contrast or CT scans at two to three month intervals after therapies are administered.
“The hope is that this study will lead to more personalized, targeted treatment for patients with a very serious cancer,” he says.
This study is being funded by ChemoID. Marko cites no conflict of interest.
*Photo credit: Colleen Kelley / University of Cincinnati, Communication Services
To find out more about enrolling in the study, call 513-418-2282.
Related Stories
University of Cincinnati’s IDD Education Center to Host Ninth Annual Red & Black Blast
December 18, 2025
The University of Cincinnati’s IDD Education Center will host its ninth annual Red & Black Blast on February 25, 2026, at Tangeman University Center. The signature event celebrates and supports the Center’s four programs—CEES, TAP, IMPACT Innovation, and RAAC—which create pathways in education, employment, and community life for individuals with intellectual and developmental disabilities (IDD).
Ohio looks to fast-track wastewater discharge permits
December 16, 2025
Bradford Mank, James B. Helmer Jr. Professor of Law at the University of Cincinnati, spoke with WVXU for a story about a proposal by the Ohio Environmental Protection Agency to streamline the way wastewater discharge permits are issued to data centers.
Limited IT support offered during winter season days
December 16, 2025
The IT Service Desk, powered by Digital Technology Solutions (DTS), will be closed from Wednesday, Dec. 24, through Thursday, Jan. 1, during the university’s Winter Season Days closure. The Service Desk will resume normal operations Friday, Jan. 2.